Tirzepatide kidney outcomes (SURPASS-4, post-hoc)

Evidence tier

Emerging / Investigational · Dual / triple agonist

Plain-language summary

A post-hoc analysis of SURPASS-4 (tirzepatide vs insulin glargine in T2D at high cardiovascular risk) found a lower composite kidney endpoint with tirzepatide, driven largely by reduced albuminuria. Exploratory, not a dedicated kidney-outcome trial.

Key findings

Composite kidney endpoint: HR 0.58 (95% CI 0.43–0.80) vs insulin glargine.
Slower eGFR decline and reduced UACR.

Population

Adults with type 2 diabetes and high cardiovascular risk (N=1,995 in the analysis).

What this does not prove

Post-hoc/exploratory analysis with an active comparator; not a kidney-outcome trial. A further exploratory kidney analysis of SURPASS-CVOT — against the active comparator dulaglutide (itself a GLP-1 RA), not placebo — extends the signal, but confirmation awaits dedicated trials.

Primary source

Heerspink HJL, et al. Lancet Diabetes Endocrinol. 2022.
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00243-1/abstract

Educational only

Paraphrased from the primary publication; not individual medical advice. Verify against the source before applying to care.